Muscle Loss on GLP-1s: What the Evidence Really Shows
New body composition data compares lean mass loss on tirzepatide and semaglutide. Here is what is measured, and what remains unclear.
Ask anyone who has spent a year on a GLP-1 receptor agonist what worries them most, and it is rarely the nausea. It is the fear of trading fat for muscle, of stepping off the drug lighter on the scale but weaker in the body. That worry has outpaced the data for years. It is now starting to catch up.
A wave of newer research, including a large digital phenotyping study and a dedicated body composition trial, is giving a more precise picture of how much lean mass these drugs actually cost, and which patients lose the most.
How much of the weight loss is muscle
Across GLP-1 based therapies broadly, lean mass loss has been estimated at approximately 25 percent of total weight lost, according to a synthesis of body composition data. That is not nothing, but it is also roughly proportional to what happens with non-drug weight loss through calorie restriction alone, where lean mass typically makes up a meaningful minority share of any weight lost.
Tirzepatide versus semaglutide, compared directly
A 2026 digital phenotyping analysis, published on medRxiv, found that tirzepatide was associated with greater relative lean body mass loss than semaglutide at every measured time point, with excess lean mass losses of 1.1, 1.5, 1.3 and 2.0 percentage points at 3, 6, 9 and 12 months respectively. The same analysis defined what it called a "depletive GLP-1 metabotype", more than 20 percent total body weight loss paired with more than 5 percent lean mass loss, and found this pattern significantly more common with tirzepatide, at 10.3 percent of patients, than with semaglutide, at 6.7 percent.
What predicts a bigger muscle loss
The same study identified clinical features linked to greater lean mass loss, including baseline musculoskeletal pain, with cervicalgia and knee pain showing the strongest associations, and reduced exercise tolerance during treatment as the strongest on-treatment correlate. In plain terms, patients who were already less physically active or already dealing with joint pain before starting the drug appear more likely to lose a disproportionate share of muscle rather than fat.
That finding points toward a practical, actionable idea rather than a purely observational one: if reduced activity during treatment tracks with greater lean mass loss, then maintaining or increasing physical activity, particularly resistance training, during a course of GLP-1 treatment may be one of the more meaningful levers available to protect muscle, even though the digital phenotyping study itself was observational and cannot prove that exercise causes better outcomes rather than simply correlating with them.
What a dedicated semaglutide body composition study found
The SEMALEAN study, examining semaglutide's impact on fat mass, lean mass and muscle function specifically, adds finer detail to the picture beyond the scale number, tracking function rather than just tissue mass. Findings summarized in the published SEMALEAN results reinforce that fat mass reduction outpaces lean mass reduction on average, though individual variation is considerable. Tracking muscle function rather than only muscle mass matters because a person can lose lean tissue without necessarily losing strength if the remaining muscle becomes proportionally more metabolically active, or conversely can retain muscle mass on a scan while still losing functional strength, which is why researchers increasingly argue that grip strength and mobility testing belong alongside body composition scans rather than replacing them.
Why this is described as adaptive or maladaptive, not settled
A review in Circulation frames the open scientific question precisely: is muscle loss during GLP-1 treatment an adaptive response, tissue the body no longer needs to carry once it is lighter, or a maladaptive one that leaves patients frailer even as they weigh less. A separate systematic review and network meta-analysis published in a 2024 body composition analysis found that both tirzepatide at its highest dose and semaglutide at its highest dose were the most effective agents for fat mass reduction but ranked among the least effective at preserving lean mass, a genuine tradeoff rather than a myth.
Not every study agrees on the scale of the problem. Preclinical and some human data summarized in Cell Reports Medicine argue that GLP-1 based weight loss does not produce a disproportionate loss of muscle mass or function relative to the amount of fat lost, a reminder that this remains an actively contested area rather than a closed one.
This article reports on published and preprint research and is not medical advice. Whether resistance training, protein intake changes, or a different drug or dose is appropriate to protect muscle during treatment is a conversation for a patient's own physician, ideally one who can order body composition testing rather than relying on the scale alone.
What is reasonably settled is that lean mass loss on these drugs is real and measurable, not a scare story. What remains unresolved is how much of it matters functionally for a given patient, and that is the question the next round of trials, with actual strength and mobility testing built in rather than added as an afterthought, will need to answer.
Published in The Outspoken Digest
Read Next
More Health →
The Perfect Hot Chocolate: Rich, Spicy, and Unapologetically Comforting
Jan 28, 2026/3 min read
